Dr. Reddy's Laboratories (RDY) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Is TAK or RDY more profitable?

Dr. Reddy's Laboratories has a net margin of 17.25% compared to Takeda Pharmaceutical's net margin of 4.53%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.53%	9.39%	4.53%
Dr. Reddy's Laboratories	17.25%	17.87%	12.32%

Do analysts prefer TAK or RDY?

Dr. Reddy's Laboratories has a consensus price target of $17.00, suggesting a potential upside of 18.22%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer TAK or RDY?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 6 mentions for Takeda Pharmaceutical. Dr. Reddy's Laboratories' average media sentiment score of 1.58 beat Takeda Pharmaceutical's score of 1.18 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community favor TAK or RDY?

Dr. Reddy's Laboratories received 221 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 59.41% of users gave Dr. Reddy's Laboratories an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%
Dr. Reddy's Laboratories	Outperform Votes 322 59.41%	Underperform Votes 220 40.59%

Is TAK or RDY a better dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Takeda Pharmaceutical pays out 240.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend.

Which has more volatility & risk, TAK or RDY?

Takeda Pharmaceutical has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Which has higher valuation & earnings, TAK or RDY?

Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.22	66.25
Dr. Reddy's Laboratories	$325.54B	0.04	$668M	$0.66	21.79

Do institutionals and insiders have more ownership in TAK or RDY?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats Takeda Pharmaceutical on 13 of the 19 factors compared between the two stocks.